October 2015, Vol. 4, No. 5
Genetic Counseling in Personalizing Care: A New Department in PMOLetter to Our Readers
I am pleased to announce a new department in PMO, Genetic Counseling. In each issue, PMO editorial board member Cristi Radford, MS, CGC, of the Moffitt Cancer Center will contribute an impactful article. In this issue, you will read about BRCA1/2 testing for any patient with pancreatic adenocarcinoma. If you have an intriguing case to share, I encourage you to submit it to our Editorial Director at Ksiyahian@the-lynx-group.com.
The mission of our journal is to provide a bridge between academic research and practicing clinicians by demonstrating the immediate implications of precision medicine—including advances in molecular sequencing, targeted therapies, and new diagnostic modalities—to the management of patients with cancer, offering oncologists, oncology nurses, payers, researchers, drug developers, policymakers, and all oncology stakeholders the relevant practical information they need to improve cancer outcomes. Improved outcomes lie in the ability to administer effective therapies. Our ability to prescribe effective therapies has more and more become reliant on our understanding of the molecular biology of the tumor microenvironment as well as the genomic and genetic information of the patient.
To this end, this month we offer an intriguing interview with Nazneen Aziz, PhD, of the Phoenix Children’s Hospital revealing how genetic, genomic, and biomarker information is being put to work to improve outcomes for patients. We also present a case study on molecular pathways in non–small cell lung cancer as well as several other relevant articles on the personalized approach to caring for patients with cancer.
As always, thank you for your loyal readership. We hope the addition of the genetic counseling department will be of value to you in your practice.
Al B. Benson III, MD, FACP, FASCO
Coeditor in Chief
Personalized Medicine in Oncology
New Data Suggest Clinicians Should Consider Genetic Counseling and BRCA1/2 Testing for Any Patient with Pancreatic Adenocarcinoma
Pancreatic cancer represents 3% of new cancer cases each year, with the average age of diagnosis being 71 years.1 The most common type of pancreatic cancer is pancreatic ductal adenocarcinoma (PDAC), which originates from exocrine cells. Although pancreatic cancer accounts for a small percentage of cancers each year, its survival [ Read More ]
At the 16th Annual International Lung Cancer Congress, Tony Mok, MD, Professor of Clinical Oncology, The Chinese University of Hong Kong, provided an overview of the next generation of agents, taking stock of the recent past for insights into the future of drug discovery. Drug discovery is rarely, if ever, [ Read More ]